[Immunoprophylaxis and immunotherapy of experimental Pseudomonas aeruginosa sepsis].
The protective activity of pyoimmunogen II, lot 9, was studied on P. aeruginosa experimental sepsis used as a model. In experiments on rats the preparation was shown to be nontoxic according to the results of the determination of acute and chronic toxicity. The preparation under test produced a high protective effect in experiments on animals infected with various P. aeruginosa strains, irrespective of their virulence and immunotype. Anti-P. aeruginosa plasma, obtained by plasmapheresis from donors immunized with pyoimmunogen II, showed a curative effect when injected into experimental animals in a dose of 0.02 ml/g body weight at early stages of the infection.
D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007106:Immune Sera / Q000302:isolation & purification; D007116:Immunization, Passive / Q000379:methods; D051379:Mice; D011552:Pseudomonas Infections / Q000517:prevention & control* / Q000628:therapy; D054406:Pseudomonas Vaccines; D011550:Pseudomonas aeruginosa / Q000276:immunology / Q000472:pathogenicity; D051381:Rats; D017778:Vaccines, Combined; D014774:Virulence
D001428:Bacterial Vaccines; D007106:Immune Sera; D054406:Pseudomonas Vaccines; D017778:Vaccines, Combined; C039987:polyvalent pseudomonas vaccine
Immunoprofilaktika i immunoterapiia éksperimental'nogo sinegnoĭnogo sepsisa.